Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
Definitive Healthcare Corp. reports developments in healthcare market data, analytics, and commercial intelligence for organizations operating on the business side of healthcare. Its SaaS-based platform and related solutions support use cases such as market selection, go-to-market planning, provider targeting, affiliation analysis, prescription-pattern visibility, Key Opinion Leader identification, and workflow data enrichment.
Recurring news for DH includes quarterly and annual financial results, guidance commentary, customer wins and renewals across life sciences and health-system markets, expansions involving products such as Monocl and Population Intelligence, data-integration use cases, and investor conference presentations. Company updates also describe subscription revenue trends, adjusted profitability measures, cash flow, and commercial execution across new logos and existing customers.
Definitive Healthcare (Nasdaq: DH) announced product enhancements to strengthen its healthcare data platform and integrations. Updates include expanded Atlas All-Payor Claims coverage, a new HubSpot CRM integration, direct access to affiliated HCP data in Salesforce via DefinitiveConnect, and new AI search in Monocl ExpertInsight and the View Suite.
These enhancements aim to give organizations a more complete, connected view of the healthcare ecosystem and make insights easier to use across sales, marketing, strategy, medical affairs, and product development.
Definitive Healthcare (Nasdaq: DH) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $55.9 million (down 6% YoY). Net loss was $(192.4) million, inclusive of $197.2 million goodwill impairment. Adjusted net income was $8.5 million; Adjusted EBITDA was $15.3 million (27% of revenue). Cash flow from operations was $11.6 million and unlevered free cash flow was $18.0 million. Q2 2026 and full‑year 2026 guidance ranges were provided, including full‑year revenue $220.0–$226.0 million.
Definitive Healthcare (Nasdaq: DH) will report Q1 2026 financial results for the quarter ended March 31, 2026, on Thursday, May 7, 2026 after market close. The company will host a conference call and webcast at 5:00 PM ET / 2:00 PM PT.
Live audio webcast access is available on the company’s Investor Relations website. Domestic and international dial-in numbers are provided, and a replay will be available through June 6, 2026 with passcode 1765#.
Definitive Healthcare (Nasdaq: DH) reported fourth quarter and full year 2025 results on Feb 26, 2026. Q4 revenue was $61.5M; full-year revenue was $241.5M. Adjusted EBITDA was $18.0M (29% of revenue) in Q4 and $70.4M (29% margin) for the year. Cash flow from operations was $53.8M for 2025 and unlevered free cash flow was $54.9M. The company recorded significant goodwill impairments ($196.1M full year) and reported adjusted net income of $34.9M for 2025. Guidance for 2026 projects revenue of $220.0–$226.0M and adjusted EBITDA of $53.0–$58.0M.
Definitive Healthcare (Nasdaq: DH) will report fourth quarter and full year 2025 results on Thursday, February 26, 2026 after market close. The company will host a conference call and webcast at 5:00 PM ET / 2:00 PM PT to discuss results.
Live audio webcast will be available on the company’s Investor Relations website. Domestic dial-in is 877-358-7298; international dial-in is +1-848-488-9244. A replay will be available through March 26, 2026 with passcode 1765#.
Definitive Healthcare (Nasdaq: DH) announced that its Chief Financial Officer, Casey Heller, will present at the 28th Annual Needham Growth Conference. The presentation is scheduled for Wednesday, January 14, 2026 at 9:30 a.m. ET.
A live webcast will be available on the company's investor relations Events page and a replay will be posted for a limited time.
Definitive Healthcare (Nasdaq: DH) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $60.0M (down 4% YoY). Net loss was $(17.8)M; prior-year Q3 included a $228.2M goodwill impairment. Adjusted net income was $9.7M and Adjusted EBITDA was $18.9M (32% of revenue). Operating cash flow was $15.7M and unlevered free cash flow was $17.9M. Management said Q3 results met or exceeded guidance, noting a $2M Adjusted EBITDA beat and improvements in new-logo production and retention.
Outlook: Q4 2025 revenue guidance of $59.0–$60.0M; full-year 2025 revenue raised to $239.0–$240.0M (bottom end +$2.0M); full-year Adjusted EBITDA expected $68.0–$69.0M.
Definitive Healthcare (Nasdaq: DH) will report third quarter results for the period ended September 30, 2025 on Thursday, November 6, 2025 after market close.
The company will host a conference call and webcast on that date at 5:00 PM ET / 2:00 PM PT. A live audio webcast will be available on the company investor relations site at https://ir.definitivehc.com/. Live dial-in numbers are 877-358-7298 (domestic) and +1-848-488-9244 (international).
A replay will be available through December 6, 2025 at 800-645-7964 or 757-849-6722 using passcode 1765#.
Definitive Healthcare (NASDAQ:DH), a healthcare commercial intelligence company, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. CEO Kevin Coop and CFO Casey Heller will deliver a presentation on Tuesday, September 9, 2025, at 9:15 a.m. ET.
Investors can access a live webcast of the presentation through the Events section of Definitive Healthcare's investor relations website at ir.definitivehc.com. A replay will be available for a limited time after the event.
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence leader, reported mixed Q2 2025 financial results. Revenue declined 5% year-over-year to $60.8 million, while net loss improved to $(9.3) million from $(306.2) million in Q2 2024. Adjusted EBITDA was $18.7 million, representing a 31% margin.
The company secured notable customer wins, including a healthcare revenue cycle management firm and a returning digital health organization. Based on H1 2025 progress, management raised guidance, projecting full-year 2025 revenue of $237.0-$240.0 million and adjusted EBITDA of $64.0-$67.0 million with 27-28% margins.